Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | GMNN | O75496 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | TSPO | P30536 | 1/20 | 0.30 |
| ▸ | BLM | P54132 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24068030 | 0.81 | SMN1; SMN2 (0.40) | KDM4EALDH1A1MAPTLMNAPOLB | |
| SCHEMBL24068077 | 0.80 | MEN1 (0.33) | KDM4EALDH1A1LMNACYP3A4NPSR1 | |
| SCHEMBL24068085 | 0.74 | KDM4E (0.35) | KDM4EALDH1A1MAPTGMNNLMNA | |
| SCHEMBL24068096 | 0.72 | CHEK1 (0.43) | ALDH1A1CYP3A4 | |
| SCHEMBL13193039 | 0.70 | KDM4E (0.33) | KDM4EMAPTLMNA | |
| SCHEMBL24068083 | 0.70 | KDM4E (0.33) | KDM4E | |
| SCHEMBL24068074 | 0.70 | KDM4E (0.33) | KDM4ELMNA | |
| SCHEMBL21248397 | 0.68 | — | — | |
| SCHEMBL21256133 | 0.67 | — | — | |
| SCHEMBL24104013 | 0.60 | HPGD (0.30) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115667257-B | Compounds for inhibiting CDK7 | 伊莱利利公司 | 2024-06-11 | — | — | CN | disclosed |
| US-20230203031-A1 | COMPOUNDS USEFUL FOR INHIBITING CDK7 | ELI LILLY AND COMPANY | 2023-06-29 | — | — | US | disclosed |
| US-20230203031-A1 | COMPOUNDS USEFUL FOR INHIBITING CDK7 | ELI LILLY AND COMPANY | 2023-06-29 | — | — | US | disclosed |
| US-20230203031-A1 | COMPOUNDS USEFUL FOR INHIBITING CDK7 | ELI LILLY AND COMPANY | 2023-06-29 | — | — | US | disclosed |
| EP-4157840-A1 | COMPOUNDS USEFUL FOR INHIBITING CDK7 | Eli Lilly and Company (US) | 2023-04-05 | — | — | EP | disclosed |
| CN-115667257-A | Compounds for inhibiting CDK7 | 伊莱利利公司 | 2023-01-31 | — | — | CN | disclosed |
| WO-2021242602-A1 | COMPOUNDS USEFUL FOR INHIBITING CDK7 | ELI LILLY AND COMPANY (US) | 2021-12-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230203031-A1 | COMPOUNDS USEFUL FOR INHIBITING CDK7 | CDK7, CDK3, CCNH | KDM4E 430/4885ALDH1A1 3476/4885MAPT 3657/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.